Emestedastat

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Pharmaceutical compound

Emestedastat (proposed brand name Xanamem; developmental code name UE-2343) is a steroidogenesis inhibitor which is under development for the treatment of Alzheimer's disease, major depressive disorder, and fragile X syndrome.[1][2] It is taken orally.[1]

The drug specifically acts as a centrally penetrant inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and thereby inhibits the synthesis of the glucocorticoid steroid hormone cortisol.[1][3][4][2]

Emestedastat was originated by the University of Edinburgh and is under development by Actinogen Medical.[1] As of June 2026, it is in phase 2/3 clinical trials for Alzheimer's disease and phase 2 trials for major depressive disorder, whereas no recent development has been reported for fragile X syndrome.[1][2]

Clinical effectiveness for Alzheimer's disease has been mixed.[2] In a phase 2 clinical trial for major depressive disorder published in July 2026, emestedastat showed no significant benefit on depressive or cognitive symptoms.[5] In addition, it produced mild-to-moderate transaminase elevations in 10% of people, whereas this occurred in 1% in the placebo group.[5]

See also

edit edit source

References

edit edit source
  1. ^ a b c d e f "Emestedastat (UE-2343; Xanamem)". AdisInsight. 28 August 2024. Retrieved 9 October 2024.
  2. ^ a b c d Seckl J (January 2024). "11β-Hydroxysteroid dehydrogenase and the brain: Not (yet) lost in translation". Journal of Internal Medicine. 295 (1): 20–37. doi:10.1111/joim.13741. PMID 37941106.
  3. ^ Bachurin SO, Gavrilova SI, Samsonova A, Barreto GE, Aliev G (March 2018). "Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention". Pharmacological Research. 129: 216–226. doi:10.1016/j.phrs.2017.11.021. PMID 29170097.
  4. ^ Canet G, Hernandez C, Zussy C, Chevallier N, Desrumaux C, Givalois L (2019). "Is AD a Stress-Related Disorder? Focus on the HPA Axis and Its Promising Therapeutic Targets". Frontiers in Aging Neuroscience. 11 269. doi:10.3389/fnagi.2019.00269. PMC 6776918. PMID 31611783.
  5. ^ a b Taylor JD, Rolan PE, Jaros MJ, Harrison JE, Ratcliffe SH, Berk M, et al. (July 2026). "A Phase 2 randomised, double-blind, placebo-controlled trial of emestedastat in patients with major depressive disorder and cognitive impairment". Br J Psychiatry: 1–8. doi:10.1192/bjp.2026.10689. PMID 42464916.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1371059574 under CC BY-SA 4.0; modifications have been made.

References

  1. ↩Wikipedia “Emestedastat” revision 1371059574 · retrieved 2026-10-20 publication date (×1) · confidence 0.95 revision URL